Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation - Wikidata - awgldk - TriplyDB

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation

http://www.wikidata.org/entity/Q33401421

about

Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes New IDH1 mutant inhibitors for treatment of acute myeloid leukemia Refractory anemia with ring sideroblasts and RARS with thrombocytosis Eltrombopag in aplastic anemia Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.Supportive care for thrombocytopenia in patients receiving treatment for myelodysplasia: a challenge for the future.Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia.A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.The Eltrombopag antitumor effect on hepatocellular carcinoma.Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation Eltrombopag, a thrombopoietin mimetic, crosses the blood-brain barrier and impairs iron-dependent hippocampal neuron dendrite development.From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag.Effects of iron depletion on CALM-AF10 leukemias.Iron deprivation in cancer--potential therapeutic implications Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.Iron chelation therapy in low risk myelodysplastic syndrome.Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.Eltrombopag, a potent stimulator of megakaryopoiesis.Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia.C-MPL provides tumor-targeted T cell receptor-transgenic T cells with co-stimulation and cytokine signals.Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia.Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia.Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism.Eltrombopag mobilizes iron in patients with aplastic anemia.Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer.Thrombocytopenia in Patients with Myelodysplastic Syndromes: Still an Unsolved Problem.

P2860

Q26863182-5D25C05F-F085-4D9B-9955-1CCEE39B2F09 Q27702240-734D0F7B-2ED3-4E4F-B197-4CFA596FEAC1 Q28083238-60F95BB8-0642-4C2F-BFA3-B65B1CCF8716 Q28085299-0F800E26-5CF2-4319-B416-5B190E7DB97B Q28546734-CBECF50C-BDAF-41DE-AEF3-2182C3AECA7E Q30399669-9528EDDA-A9DF-4368-B58B-DDF5A61B864E Q33403765-C0B14EBF-7B10-4B1D-BB82-655DB976C304 Q33411387-FB01172A-0FAA-439B-8312-21658C50F5B4 Q33414087-E6E4CE78-3DDE-4316-A0A4-78DD9FCF29B5 Q33414386-E75A9F6F-6E41-467E-AD1F-760248C34609 Q33415466-E5464105-8D47-4664-BCB9-43E35E662350 Q33426135-478CE48E-0401-4C73-9333-B4C36225B3D0 Q33427023-CF17000B-323E-4F02-A202-C5DC2915DED4 Q33434519-B3D9CC30-1891-47CF-87BB-5462E50DC557 Q33437814-2F1F4FB7-6E68-4112-8BD8-67F536BF5C2C Q33441627-87FC5E75-DECB-4BC2-B152-149BBDA30352 Q34663999-A3F7B46F-6713-4748-B4D8-EC493843648E Q37177365-742D961B-7BDB-49CC-99D8-2B616D91F92C Q38832241-9D2D6641-A9BC-4A4A-8659-3222B1CB45A8 Q38903926-088BF4A2-0C07-4BCB-88F5-24A454047B66 Q39131365-91274EC4-E704-4BF4-A1EE-B5E346F7DEAE Q42335815-31526217-01EC-438E-A254-4870F74B496B Q43057959-1122F4C1-B0F7-4894-A6CC-AF30C88020B4 Q45873673-44DA83E8-1040-43C1-87A7-5C26F39FFF5C Q48191068-2D24405C-AC09-47D3-9F42-47D764344A1A Q48592284-18C63714-6FD8-4BD3-8CC7-C594D684EBB8 Q51102707-7D932DF8-6A07-474E-90A7-9234BEE78B3A Q52597951-F4CD021F-D06D-4C1C-8B9E-363995738829 Q52846906-601EFE40-702C-47E7-ACE9-2A0D4A5FFCD5 Q55666053-DB3BD781-F1D4-44E5-8298-2F695EB6B99F

P2860

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation

http://www.wikidata.org/entity/Q33401421

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Eltrombopag inhibits the proli ...... d induction of differentiation

@ast

Eltrombopag inhibits the proli ...... d induction of differentiation

@en

type

label

Eltrombopag inhibits the proli ...... d induction of differentiation

@ast

Eltrombopag inhibits the proli ...... d induction of differentiation

@en

prefLabel

Eltrombopag inhibits the proli ...... d induction of differentiation

@ast

Eltrombopag inhibits the proli ...... d induction of differentiation

@en

P1433

Q33401421-6057E1E1-0759-4734-B53E-3C2AD31C15E9

P1476

Q33401421-FB28FE08-9F0F-47A9-BE6D-AA5AF073D925

P2093

Q33401421-32FF723F-6D6B-4109-80A9-6184A71CB923

Q33401421-5CBAA39C-76F7-4710-B6BD-62A846EF8684

Q33401421-60985E00-CE53-400F-AF8C-C8548996E15E

Q33401421-715F6133-5C16-4E69-8D8C-4306EF2EB78F

Q33401421-719693B3-5289-485F-8BDE-EEEDE53672EF

Q33401421-A59BFAC3-A861-4F0F-A2AD-B2A657D3EF0F

Q33401421-F185F2C8-1A56-46F9-BDB3-C6FBEDE3564F

Q33401421-FE747439-9E20-49A6-A231-A58DCABF3BBB

Q33401421-FE99D5EA-A484-4FAF-849D-E60C80178524

P2860

Q33401421-011B22B6-305C-4D97-AB32-5327513FFF4F

Q33401421-063661AA-37C1-4EE7-91B5-BF0DFE637597

Q33401421-12461C69-06D4-4039-A3EA-6AB88FA0C510

Q33401421-174CF390-3435-4791-AFF9-9EC7FD20CB39

Q33401421-2E444765-9948-40F8-82D6-7F5B62AE95F5

Q33401421-311A6062-6964-4DEB-A2EE-558449F9544A

Q33401421-3A9FF50B-5CF7-4B60-BBCE-8D510D83D0C2

Q33401421-3C7A37B4-191F-4F67-93A4-EAF5DAF8D768

Q33401421-3D9A1289-9DAF-4820-9EBA-41B570397C41

Q33401421-49210240-2C12-4915-B7DC-152B3C5A2C69

P304

Q33401421-4E303A7D-C109-48B0-A85F-4722C78BB9D2

P31

Q33401421-4C8B7102-0D11-4D27-ADDD-26FC7DCF1F75

P356

Q33401421-7F975294-DB3A-4DFA-97C6-129444DE1455

P407

Q33401421-72F6742C-B89E-434E-A827-95EE2DF1DC17

P433

Q33401421-600F8AC2-875C-4545-8932-AAB69EB60548

P478

Q33401421-54BC4121-4206-40DD-8270-0D2B1FD1865B

P50

Q33401421-2B4FAD96-035F-4E28-B532-355B1B3DA37A

P577

Q33401421-34F6CF92-5B4D-484E-A6E5-9685E2EAF915

P5875

Q33401421-DBD5B278-4D03-41A5-B587-BF19E146F5FB

P698

Q33401421-D0DAC4D1-62CD-49A7-9CDF-88B57A70CB2E

P921

Q33401421-A00972A3-C6EF-4BBF-B22B-D1E0273B134A

P932

Q33401421-4F6B0C93-212D-4A0A-83E0-455A6CBB1F69

P356

BLOOD-2011-12-399667

P1433

P1476

Eltrombopag inhibits the proli ...... d induction of differentiation

@en

P2093

Amit Verma

http://www.w3.org/2001/XMLSchema#string

Boris Bartholdy

http://www.w3.org/2001/XMLSchema#string

Constantine S Mitsiades

http://www.w3.org/2001/XMLSchema#string

Guillermo Simkin

http://www.w3.org/2001/XMLSchema#string

Laura Barreyro

http://www.w3.org/2001/XMLSchema#string

Michael Roth

http://www.w3.org/2001/XMLSchema#string

Roni Tamari

http://www.w3.org/2001/XMLSchema#string

Swathi Narayanagari

http://www.w3.org/2001/XMLSchema#string

Ulrich Steidl

http://www.w3.org/2001/XMLSchema#string

P2860

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.

The incidence and impact of thrombocytopenia in myelodysplastic syndromes.

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.

Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.

Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome.

A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.

P304

386-394

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-12-399667

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225043722

http://www.w3.org/2001/XMLSchema#string

P698

22627766

http://www.w3.org/2001/XMLSchema#string

P921

P932

3398759

http://www.w3.org/2001/XMLSchema#string